Protected: Combining rivaroxaban with aspirin in stable atherosclerotic vascular disease: clinical evidence from the COMPASS study

Br J Cardiol 2020;27(suppl 1):S15–S20doi:10.5837/bjc2020.s04
Click any image to enlarge
Authors:
Sponsorship Statement: Bayer plc. commissioned and funded this supplement. The company has reviewed the data to ensure factual accuracy in relation to Bayer products and compliance with industry guidelines. Rivaroxaban prescribing information current at the time of publication is available here.
Job code: PP-XAR-GB-1131
Date of preparation: January 2020

For notes on dosing recommendations from Xarelto® ▼ (rivaroxaban) SmPC (Summary of Product Characteristics) please see the box at the foot of this page

There is no excerpt because this is a protected post.

This content is password protected. To view it please enter your password below:

Disclaimer: Medinews Cardiology Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews Cardiology Limited cannot accept responsibility for any errors in prescribing which may occur.